While research has shown that amyloid PET is more accurate for diagnosing AD in the earliest stages, recent studies suggest that tau‐PET, a newer technique, may be more advantageous for determining the disease stage and predicting disease progression. The gene discussed is MAPT; the disease is Alzheimer disease.